KSQ Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exclusive, global rights to develop, manufacture and commercialize cell and non-cell therapies that modulate targets identified with KSQ's CRISPRomics platform. The deal includes up to...

Verve’s non-human primate data makes the case that base editing can produce durable and efficient changes in protein production by the liver, with a clear route to protection from heart attack. Six-month data shared by...

Myriad’s autoimmune unit on the blockMyriad Genetics Inc. (NASDAQ:MYGN) said it will focus on women’s health, cancer and mental health and pursue strategic alternatives for its autoimmune unit. In November on its earnings call, the...